144 related articles for article (PubMed ID: 34961618)
1. Iodine-131 and Iodine-131-Meta-iodobenzylguanidine Dosimetry in Cancer Therapy.
Flux G; Leek F; Gape P; Gear J; Taprogge J
Semin Nucl Med; 2022 Mar; 52(2):167-177. PubMed ID: 34961618
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
[TBL] [Abstract][Full Text] [Related]
3. Clinical applications of dosimetry for mIBG therapy.
Flux GD; Chittenden SJ; Saran F; Gaze MN
Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):116-25. PubMed ID: 21386786
[TBL] [Abstract][Full Text] [Related]
4. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".
Flux G; Bardies M; Chiesa C; Monsieurs M; Savolainen S; Strand SE; Lassmann M
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1699-700. PubMed ID: 17565497
[No Abstract] [Full Text] [Related]
5. Dosimetric results in treatments of neuroblastoma and neuroendocrine tumors with (131)I-metaiodobenzylguanidine with implications for the activity to administer.
Mínguez P; Flux G; Genollá J; Guayambuco S; Delgado A; Fombellida JC; Sjögreen Gleisner K
Med Phys; 2015 Jul; 42(7):3969-78. PubMed ID: 26133597
[TBL] [Abstract][Full Text] [Related]
6. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
8. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model.
Seo Y; Gustafson WC; Dannoon SF; Nekritz EA; Lee CL; Murphy ST; VanBrocklin HF; Hernandez-Pampaloni M; Haas-Kogan DA; Weiss WA; Matthay KK
Mol Imaging Biol; 2012 Dec; 14(6):735-42. PubMed ID: 22382618
[TBL] [Abstract][Full Text] [Related]
9. The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer.
Taprogge J; Abreu C; Yusuf S; Ainsworth G; Phillip RH; Gear JI; Gregory R; Leek F; Murray I; Coulson AB; Brown SR; Du Y; Newbold K; Wadsley J; Flux GD
J Nucl Med; 2023 Jul; 64(7):1125-1130. PubMed ID: 37116914
[TBL] [Abstract][Full Text] [Related]
10. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans.
Monsieurs M; Brans B; Bacher K; Dierckx R; Thierens H
Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1581-7. PubMed ID: 12458391
[TBL] [Abstract][Full Text] [Related]
11. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
[TBL] [Abstract][Full Text] [Related]
12. Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy.
Rutgers M; Buitenhuis CK; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Aug; 87(3):412-22. PubMed ID: 10897048
[TBL] [Abstract][Full Text] [Related]
13. Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma.
Huang SY; Bolch WE; Lee C; Van Brocklin HF; Pampaloni MH; Hawkins RA; Sznewajs A; DuBois SG; Matthay KK; Seo Y
Mol Imaging Biol; 2015 Apr; 17(2):284-94. PubMed ID: 25145966
[TBL] [Abstract][Full Text] [Related]
14. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study.
Fielding SL; Flower MA; Ackery D; Kemshead JT; Lashford LS; Lewis I
Eur J Nucl Med; 1991; 18(5):308-16. PubMed ID: 1936038
[TBL] [Abstract][Full Text] [Related]
15. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".
Brans B; Bodei L; Giammarile F; Linden O; Luster M; Oyen WJG; Tennvall J
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):772-786. PubMed ID: 17268773
[TBL] [Abstract][Full Text] [Related]
16. Physics aspects of setting up a multicenter clinical trial involving internal dosimetry of radioiodine treatment of differentiated thyroid cancer.
Taprogge J; Leek F; Flux GD
Q J Nucl Med Mol Imaging; 2019 Sep; 63(3):271-277. PubMed ID: 31315346
[TBL] [Abstract][Full Text] [Related]
17. Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule.
Sgouros G; Song H; Ladenson PW; Wahl RL
J Nucl Med; 2006 Dec; 47(12):1977-84. PubMed ID: 17138740
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Pharmacokinetics and Dosimetry Studies of
Marsh IR; Grudzinski J; Baiu DC; Besemer A; Hernandez R; Jeffery JJ; Weichert JP; Otto M; Bednarz BP
J Nucl Med; 2019 Oct; 60(10):1414-1420. PubMed ID: 30926646
[TBL] [Abstract][Full Text] [Related]
19. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer.
Flux GD; Haq M; Chittenden SJ; Buckley S; Hindorf C; Newbold K; Harmer CL
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):270-5. PubMed ID: 19760413
[TBL] [Abstract][Full Text] [Related]
20. Dosimetry in nuclear medicine therapy: what are the specifics in image quantification for dosimetry?
Bardiès M; Buvat I
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):5-20. PubMed ID: 21386782
[No Abstract] [Full Text] [Related]
[Next] [New Search]
